Hormone therapy for prostate cancer has come a long way in the past few decades. Not so long ago, the only hormonal treatment for this disease was drastic: an orchiectomy, the surgical removal of ...

Hormone therapy can make a big difference for men with recurrent or metastatic prostate cancer. But it isn't a cure. Its effects are limited and the side effects can be difficult to cope with.

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The findings could lead to the development of new drugs with fewer side effects, ...

It has seen patients take abiraterone, which stops the body producing the hormone testosterone, in combination with standard treatment for locally advanced prostate cancer. Prostate cancer ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

790 patients with treatment-na-ve hormone-sensitive metastatic prostate cancer were randomized to either ADT plus docetaxel or ADT alone. [7] The primary end point of this study was OS.

independent of the traditional methods for prostate cancer elimination that include hormone therapy, chemotherapy, and various methods of radiation therapy. "Because the CAR-T program uses a novel ...

ADT, androgen-deprivation therapy; DOC, docetaxel; FDA, US Food and Drug Administration; mHSPC, metastatic hormone-sensitive prostate cancer; RCT, randomized controlled trial. We considered the ...

A clinical trial for prostate cancer testing the BCL2 inhibitor venetoclax—a drug approved for types of leukemia—with the ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...